Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

NEXT STORY
Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion
PREV STORY
Why COVID is just the tip of a terrifying, but potentially revolutionary, antibiotic resistant iceberg
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

BioNTech to Report Third Quarter Financial Results and Operational Update on November 9, 2021

author_avatar
NASDAQ Market News

Cempra Presents Data at ECCMID Highlighting Need for New CABP Therapies and Activity of Solithromycin in Key Population Groups

CHAPEL HILL, N.C., April 21, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage ...

author_avatar
NASDAQ Market News

AACR 2019 Presentations Highlight CX-2009, a First-In-Class Probody Drug Conjugate Targeting Novel Tumor Antigen, CD166

author_avatar
NASDAQ Market News